Neuren will leave no stone unturned following the submission of the Orphan Drug and Breakthrough Therapy applications. Going back to the pre-IND meeting with the FDA on the [then] proposed Rett Syndrome clinical trials, Neuren were accompanied by representatives of the International Rett Syndrome Foundation and Autism Speaks.
Advocates for patients and families affected by Rett Syndrome could provide the gravitas for expediting drug approval off the back of Phase 2 results.
There may be others cheering from the sidelines.
The US Army for one who have a vested interest in the early approval of NNZ-2566. Another group could be unspecified 'international pharmaceutical companies' who have picked up the phone following the results of the Phase 2 trial.
clock is ticking, page-7
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.73 |
Change
-0.240(1.20%) |
Mkt cap ! $2.535B | |||
| Open | High | Low | Value | Volume |
| $19.96 | $19.96 | $19.69 | $2.059M | 103.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 701 | $19.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.74 | 197 | 8 |
View Market Depth
| Last trade - 13.32pm 05/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |